Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Valerio Alonzi"'
Autor:
Paolo Cameli, Valerio Alonzi, Miriana d’Alessandro, Laura Bergantini, Elena Pordon, Marco Guerrieri, Rosa Metella Refini, Piersante Sestini, Elena Bargagli
Publikováno v:
Biomedicines, Vol 10, Iss 8, p 1973 (2022)
Background: Nintedanib is an oral multitarget tyrosine kinase inhibitor approved for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Recent evidence demonstrated that nintedanib reduced functional disease progression also in subje
Externí odkaz:
https://doaj.org/article/43befbd2cc1542c7a21a6fd4eb74f27a
Autor:
Paolo Cameli, Rosa Metella Refini, Laura Bergantini, Miriana d’Alessandro, Valerio Alonzi, Carlo Magnoni, Paola Rottoli, Piersante Sestini, Elena Bargagli
Publikováno v:
Frontiers in Molecular Biosciences, Vol 7 (2020)
BackgroundPirfenidone and nintedanib are the sole pharmacological therapies currently approved for idiopathic pulmonary fibrosis (IPF). Limited comparison data is available in literature, despite they are both prescribed for mild-to-moderate disease.
Externí odkaz:
https://doaj.org/article/42a0ca1d9b58475d9c4c22581ca868e8
Autor:
Nicola Lanzarone, Felice Perillo, Rosa Metella Refini, Anna Perrone, Francesco Bianchi, Valerio Alonzi, Paolo Cameli, Maria Pieroni, Miriana d'Alessandro, Piersante Sestini, Claudia Landi, Laura Bergantini, Elena Bargagli
Publikováno v:
Panminerva Medica. 64
Introduction Fibrotic hypersensitivity pneumonitis (fHP) is a frequently misdiagnosed fibrosing interstitial pneumonia, which often remains undiagnosed due to the lack of uniformity of diagnostic criteria. Its features are similar to those of other I
Autor:
Elena Bargagli, Piersante Sestini, Valerio Alonzi, Maria Pieroni, Rosa Metella Refini, Laura Bergantini, Miriana d'Alessandro, Paolo Cameli
Publikováno v:
Idiopathic interstitial pneumonias.
Autor:
Piersante Sestini, Valerio Alonzi, Paolo Cameli, Lorenzo Alderighi, Elena Bargagli, Miriana d'Alessandro, Matteo Fanetti, Rosa Metella Refini, Martina Armati, Laura Bergantini
Publikováno v:
International immunopharmacology. 95
Background Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease limited to the lungs. Immunological dysregulation may significantly participate in the pathophysiology of IPF. The immunological responses to nintedanib
Autor:
Elena Bargagli, Maria Pieroni, Laura Bergantini, Miriana d'Alessandro, Rosa Metella Refini, Valerio Alonzi, Piersante Sestini, Lucia Vietri, Paolo Cameli, Francesco Bonella, Nicola Lanzarone
Publikováno v:
Biomarkers in medicine. 14(8)
Aim: Interstitial lung diseases (ILD) are a group of lung disorders characterized by interstitial lung thickening. Krebs von den Lungen-6 (KL-6) is a molecule that is predominantly expressed by damaged alveolar type II cells and it has been proposed
Autor:
Piersante Sestini, Nicola Lanzarone, Maria Antonietta Mazzei, Valerio Alonzi, Laura Bergantini, Miriana d'Alessandro, Elena Bargagli, Paolo Cameli
Publikováno v:
European journal of clinical investigationREFERENCES.
Background Serum Krebs von den Lungen-6 (sKL-6) is an high-molecular-weight (200 kDa) glycoprotein predominantly expressed by damaged alveolar type II cells, and it has been proposed as a potential biomarker of different ILD. This is a prognostic bio
Autor:
Piersante Sestini, Lucia Vietri, Maria Antonietta Mazzei, Francesco Bianchi, Valerio Alonzi, Anna Perrone, Laura Bergantini, Paolo Cameli, Elena Bargagli, Paola Rottoli, Luca Volterrani, Maria Pieroni, Rosa Metella Refini, Miriana d'Alessandro, Nicola Lanzarone, Francesco Gentili
Chronic hypersensitivity pneumonitis (cHP) is a fibrotic interstitial lung disease (ILD) resulting from inhalation of different organic substances and chemical compounds determining an inflammatory and immunological response in sensitized individuals
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ecde0e21b0226f2c7b98a6e67215bb3
http://hdl.handle.net/11365/1094871
http://hdl.handle.net/11365/1094871
Autor:
Paola Rottoli, Valerio Alonzi, Rosa Metella Refini, Elena Bargagli, Piersante Sestini, Laura Bergantini, Miriana d'Alessandro, Paolo Cameli, Carlo Magnoni
Publikováno v:
Frontiers in Molecular Biosciences
Frontiers in Molecular Biosciences, Vol 7 (2020)
Frontiers in Molecular Biosciences, Vol 7 (2020)
Background Pirfenidone and nintedanib are the sole pharmacological therapies currently approved for idiopathic pulmonary fibrosis (IPF). Limited comparison data is available in literature, despite they are both prescribed for mild-to-moderate disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f41ce18ee8f75effd21c477db090aaa
http://hdl.handle.net/11365/1118130
http://hdl.handle.net/11365/1118130
Autor:
Laura Bergantini, Paola Rottoli, Rosa Metella Refini, Francesco Bianchi, Valerio Alonzi, Elena Bargagli, Maria Antonietta Mazzei, Miriana d'Alessandro, Francesco Gentili, Maria Pieroni, Nicola Lanzarone, Piersante Sestini
Publikováno v:
ILD/DPLD of known origin.